Overview

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2023-11-28

Target enrollment:

Participant gender:

Summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. Study details include: - Study Duration per participant: Approximately 4 months - M9140 is not available through an expanded access program

Phase:

Phase 1

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborator:

Merck KGaA, Darmstadt, Germany